Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Core Viewpoint - Aquestive Therapeutics is advancing its investigational product Anaphylm, an epinephrine sublingual film, aimed at providing a reliable and portable treatment for severe allergic reactions, including anaphylaxis, with results to be presented at the 2025 AAAAI Annual Meeting [1][2]. Group 1: Product Development and Clinical Data - Anaphylm is designed to offer a more accessible option for emergency epinephrine administration without the need for an injection or device, pending FDA approval [2]. - The Phase 2 OASIS study involved 36 adults with Oral Allergy Syndrome, demonstrating that Anaphylm maintains stability and potency under extreme conditions, which is crucial for real-world application [2][4]. - Anaphylm showed consistent epinephrine absorption and matched or exceeded intramuscular (IM) epinephrine in key pharmacokinetic parameters, with median symptom resolution time of 12 minutes compared to 74 minutes without treatment [5][4]. Group 2: Presentation Details - Multiple posters will be presented at the AAAAI Annual Meeting, including topics on the durability of Anaphylm under real-world use, stability under extreme temperature conditions, and pharmacokinetic and pharmacodynamic responses [3][6]. - The lead authors for the presentations include Steve Wargacki, PhD, and Carl N. Kraus, MD, with specific presentation times scheduled for March 1, 2025 [3][6]. Group 3: Company Overview - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, with a portfolio that includes five commercialized products and collaborations with other pharmaceutical companies [8]. - The company is also developing an earlier-stage epinephrine prodrug topical gel for various dermatology conditions, showcasing its commitment to addressing complex medical needs [8].